StockData
Ocular Therapeutix, Inc logo

Ocular Therapeutix, Inc (OCUL) stock

OCULNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 9, 2026Score 3/3011% above fair value
$6.02+0.01 (+0.17%)

Close on Nov 17, 2026Market cap $1.32BP/E –Yield –

Ocular Therapeutix ebitda

EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.

Ocular Therapeutix's ebitda for the twelve months ending Jun 30, 2026 was -$308.46M. For fiscal 2025 it was -$265.69M. The highest annual figure on record is -$12.50M in fiscal 2013.

Annual ebitda

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$265.69M–
FY2024Dec 31, 2024-$168.00M–
FY2023Dec 31, 2023-$79.40M–
FY2022Dec 31, 2022-$76.55M–
FY2021Dec 31, 2021-$75.62M–
FY2020Dec 31, 2020-$60.07M–
FY2019Dec 31, 2019-$83.27M–
FY2018Dec 31, 2018-$56.83M–
FY2017Dec 31, 2017-$60.30M–
FY2016Dec 31, 2016-$42.45M–
FY2015Dec 31, 2015-$37.44M–
FY2014Dec 31, 2014-$26.55M–
FY2013Dec 31, 2013-$12.50M–
FY2012Dec 31, 2012-$13.27M–

Quarterly ebitda

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$80.26M–
Q1 FY2026Mar 31, 2026-$92.06M–
Q4 FY2025Dec 31, 2025-$68.51M–
Q3 FY2025Sep 30, 2025-$67.63M–
Q2 FY2025Jun 30, 2025-$66.62M–
Q1 FY2025Mar 31, 2025-$62.94M–
Q4 FY2024Dec 31, 2024-$49.63M–
Q3 FY2024Sep 30, 2024-$45.04M–
Q2 FY2024Jun 30, 2024-$42.63M–
Q1 FY2024Mar 31, 2024-$30.70M–
Q4 FY2023Dec 31, 2023-$19.09M–
Q3 FY2023Sep 30, 2023-$18.32M–
Q2 FY2023Jun 30, 2023-$19.92M–
Q1 FY2023Mar 31, 2023-$22.07M–
Q4 FY2022Dec 31, 2022-$18.87M–
Q3 FY2022Sep 30, 2022-$21.04M–
Q2 FY2022Jun 30, 2022-$19.36M–
Q1 FY2022Mar 31, 2022-$17.28M–
Q4 FY2021Dec 31, 2021-$17.48M–
Q3 FY2021Sep 30, 2021-$18.94M–
Q2 FY2021Jun 30, 2021-$19.62M–
Q1 FY2021Mar 31, 2021-$19.58M–
Q4 FY2020Dec 31, 2020-$13.68M–
Q3 FY2020Sep 30, 2020-$13.34M–
Q2 FY2020Jun 30, 2020-$17.18M–
Q1 FY2020Mar 31, 2020-$15.88M–
Q4 FY2019Dec 31, 2019-$20.73M–
Q3 FY2019Sep 30, 2019-$22.48M–
Q2 FY2019Jun 30, 2019-$21.00M–
Q1 FY2019Mar 31, 2019-$19.07M–
Q4 FY2018Dec 31, 2018-$16.70M–
Q3 FY2018Sep 30, 2018-$14.24M–
Q2 FY2018Jun 30, 2018-$13.00M–
Q1 FY2018Mar 31, 2018-$12.89M–
Q4 FY2017Dec 31, 2017-$12.19M–
Q3 FY2017Sep 30, 2017-$14.71M–
Q2 FY2017Jun 30, 2017-$17.99M–
Q1 FY2017Mar 31, 2017-$15.41M–
Q4 FY2016Dec 31, 2016-$12.22M–
Q3 FY2016Sep 30, 2016-$9.02M–

More Ocular Therapeutix figures

See a number that looks wrong?